Antiretroviral therapy in AIDS patients with CMV disease: Impact on the survival and long-term treatment outcome - 08/08/11
Summary |
Objectives |
To determine the impact of antiretroviral therapy (ART) on the long-term survival of AIDS patients with CMV disease and evaluate long-term outcomes of ART.
Methods |
A retrospective cohort study was conducted among HIV-infected patients with CMV disease in a medical school hospital during 1996–2005 and followed-up until June 2007.
Results |
There were 154 patients, mean age 34.5 years and 57.8% were male. Organ involvement of CMV disease included retina (94.8%), central nervous system, lungs, and gastrointestinal tract. Median CD4 cell count was 20cells/mm3 and 99 patients received ART. During median follow-up of 32 months (interquartile range 23–96), 29.2% of patients died. From Kaplan–Meier analysis, median survival is significantly longer in patients receiving ART (>116.2 vs. 21.6 months, log-rank test, p<0.001). From Cox's proportional hazard model, ART (HR 0.6, p<0.001) and previous opportunistic infections (HR 3.5, p=0.025) were negatively and positively associated with death, respectively. At median time of 69 months (interquartile range 34–101) in patients who received ART, 80.8% had HIV-1 RNA <50copies/mL and median CD4 was 421cells/mm3. One patient had immune reconstitution syndrome at 3 months after initiation of ART and resulted in permanent vision loss.
Conclusions |
ART significantly improves long-term survival of AIDS patients with CMV disease. Long-term virological and immunological outcomes are durable.
Le texte complet de cet article est disponible en PDF.Keywords : HIV, CMV, Antiretroviral therapy, Survival, Treatment outcomes
Plan
The abstract of this study was presented in 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, USA, 17–20 September 2007; H-1726. |
Vol 56 - N° 1
P. 40-43 - janvier 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?